Emma J. Dennett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emma J. Dennett has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Rebecca Normansell
St George's, University of London; Cochrane Airways, Population Health Research Institute; London UK SW17 0RE
2 shared publications - Aakar Shah
CABI
1 shared publication Alexander G. Mathioudakis
Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK
1 shared publicationAnne Dunleavy
St George's University Hospitals NHS Foundation Trust; London UK
1 shared publicationAnne E Holland
Alfred Health; Physiotherapy; Melbourne Victoria Australia 3181
1 shared publicationBen Sayer
St George's, University of London; Population Health Research Institute; London UK
1 shared publication
Latest Publications
- 1 August 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2019 (8)
Targeted interventions and approaches to care for people living with chronic obstructive pulmonary disease and at least one other long-term condition: a mixed methods review
This is a protocol for a Cochrane Review (Prototype). The objectives are as follows: To assess the effectiveness of integrated care pathways compared to routine care for people with COPD and one or more common comorbidities (quantitative data, RCTs). To assess the effectiveness of an adapted or targeted single COPD intervention (simple or complex) that is aimed at changing the management of people with COPD and one or more common comorbidities (quantitative data, RCTs). To identify emerging themes that describe the views and experiences of patients, carers and healthcare professionals when receiving or providing care to manage multi morbidities (qualitative data). To use a mixed methods approach to combine quantitative and qualitative data resulting from objectives 1, 2 and 3, provided that we find relevant data. If we find that we are unable to combine quantitative data and qualitative textual themes, we will present the data and themes separately. To identify any gaps in the evidence as a recommendation for further research.
- 1 August 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2019 (8)
Targeted interventions and approaches to care for people living with chronic obstructive pulmonary disease and at least one other long-term condition: a mixed methods review
This is a protocol for a Cochrane Review (Prototype). The objectives are as follows: To assess the effectiveness of integrated care pathways compared to routine care for people with COPD and one or more common comorbidities (quantitative data, RCTs). To assess the effectiveness of an adapted or targeted single COPD intervention (simple or complex) that is aimed at changing the management of people with COPD and one or more common comorbidities (quantitative data, RCTs). To identify emerging themes that describe the views and experiences of patients, carers and healthcare professionals when receiving or providing care to manage multi morbidities (qualitative data). To use a mixed methods approach to combine quantitative and qualitative data resulting from objectives 1, 2 and 3, provided that we find relevant data. If we find that we are unable to combine quantitative data and qualitative textual themes, we will present the data and themes separately. To identify any gaps in the evidence as a recommendation for further research.
- 25 June 2018
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2018 (6) , CD002741
Antibiotics for exacerbations of asthma
Background Asthma is a chronic respiratory condition that affects over 300 million adults and children worldwide. It is characterised by wheeze, cough, chest tightness, and shortness of breath. Symptoms typically are intermittent and may worsen over a short time, leading to an exacerbation. Asthma exacerbations can be serious, leading to hospitalisation or even death in rare cases. Exacerbations may be treated by increasing an individual's usual medication and providing additional medication, such as oral steroids. Although antibiotics are sometimes included in the treatment regimen, bacterial infections are thought to be responsible for only a minority of exacerbations, and current guidance states that antibiotics should be reserved for cases in which clear signs, symptoms, or laboratory test results are suggestive of bacterial infection. Objectives To determine the efficacy and safety of antibiotics in the treatment of asthma exacerbations. Search methods We searched the Cochrane Airways Trials Register, which contains records compiled from multiple electronic and handsearched resources. We also searched trial registries and reference lists of primary studies. We conducted the most recent search in October 2017. Selection criteria We included studies comparing antibiotic therapy for asthma exacerbations in adults or children versus placebo or usual care not involving an antibiotic. We allowed studies including any type of antibiotic, any dose, and any duration, providing the aim was to treat the exacerbation. We included parallel studies of any duration conducted in any setting and planned to include cluster trials. We excluded cross‐over trials. We included studies reported as full‐text articles, those published as abstracts only, and unpublished data. Data collection and analysis At least two review authors screened the search results for eligible studies. We extracted outcome data, assessed risk of bias in duplicate, and resolved discrepancies by involving another review author. We analysed dichotomous data as odds ratios (ORs) or risk differences (RDs), and continuous data as mean differences (MDs), all with a fixed‐effect model. We described skewed data narratively. We graded the results and presented evidence in 'Summary of findings' tables for each comparison. Primary outcomes were intensive care unit/high dependence unit (ICU/HDU) admission, duration of symptoms/exacerbations, and all adverse events. Seconday outcomes were mortality, length of hospital admission, relapse after index presentation, and peak expiratory flow rate (PEFR). Main results Six studies met our inclusion criteria and included a total of 681 adults and children with exacerbations of asthma. Mean age in the three studies in adults ranged from 36.2 to 41.2 years. The three studies in children applied varied inclusion criteria, ranging from one to 18 years of age. Five studies explicitly excluded participants with obvious signs and symptoms of bacterial infection (i.e. those clearly meeting current guidance to receive antibiotics). Four studies investigated macrolide antibiotics, and two studies investigated penicillin (amoxicillin and ampicillin) antibiotics; both studies using penicillin were conducted over 35 years ago. Five studies compared antibiotics versus placebo, and one was open‐label. Study follow‐up ranged from one to twelve weeks. Trials were of varied methodological quality, and we were able to perform only limited meta‐analysis. None of the included trials reported ICU/HDU admission, although one participant in the placebo group of a study including children with status asthmaticus experienced a respiratory arrest and was ventilated. Four studies reported asthma symptoms, but we were able to combine results for only two macrolide studies of 416 participants; the MD in diary card symptom score was ‐0.34 (95% confidence interval (CI) ‐0.60 to ‐0.08), with lower scores (on a 7 point scale) denoting improved symptoms. Two macrolide studies reported symptom‐free days. One study of 255 adults authors reported the percentage of symptom‐free days at 10 days as 16% in the antibiotic group and 8% in the placebo group. In a further study of 40 children study authors reported significantly more symptom‐free days at all time points in the antibiotic group compared with the usual care group. The same study reported the duration in days of the index asthma exacerbation, again favouring the antibiotic group. One study of a penicillin including 69 participants reported asthma symptoms at hospital discharge; the between‐group difference for both studies was reported as non‐significant. We combined data for serious adverse events from three studies involving 502 participants, but events were rare; the three trials reported only 10 events: five in the antibiotic group and five in the placebo group. We combined data for all adverse events (AEs) from three studies, but the effect estimate is imprecise (OR 0.99, 95% CI 0.69 to 1.43). No deaths were reported in any of the included studies. Two studies investigating penicillins reported admission duration; neither study reported a between‐group difference. In one study (263 participants) of macrolides, two participants in each arm were reported as experiencing a relapse, defined as a further exacerbation, by the six‐week time points. We combined PEFR endpoint results at 10 days for two macrolide studies; the result favoured antibiotics over placebo (MD 23.42 L/min, 95% CI 5.23 to 41.60). One study in children reported the maximum peak flow recorded during the follow‐up period, favouring the clarithromycin group, but the confidence interval includes no difference (MD 38.80, 95% CI ‐11.19 to 88.79). Grading of outcomes ranged from moderate to very low quality, with quality of outcomes downgraded for suspicion of publication bias, indirectness, imprecision, and...
- 25 June 2018
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2018 (6) , CD002741
Antibiotics for exacerbations of asthma
Background Asthma is a chronic respiratory condition that affects over 300 million adults and children worldwide. It is characterised by wheeze, cough, chest tightness, and shortness of breath. Symptoms typically are intermittent and may worsen over a short time, leading to an exacerbation. Asthma exacerbations can be serious, leading to hospitalisation or even death in rare cases. Exacerbations may be treated by increasing an individual's usual medication and providing additional medication, such as oral steroids. Although antibiotics are sometimes included in the treatment regimen, bacterial infections are thought to be responsible for only a minority of exacerbations, and current guidance states that antibiotics should be reserved for cases in which clear signs, symptoms, or laboratory test results are suggestive of bacterial infection. Objectives To determine the efficacy and safety of antibiotics in the treatment of asthma exacerbations. Search methods We searched the Cochrane Airways Trials Register, which contains records compiled from multiple electronic and handsearched resources. We also searched trial registries and reference lists of primary studies. We conducted the most recent search in October 2017. Selection criteria We included studies comparing antibiotic therapy for asthma exacerbations in adults or children versus placebo or usual care not involving an antibiotic. We allowed studies including any type of antibiotic, any dose, and any duration, providing the aim was to treat the exacerbation. We included parallel studies of any duration conducted in any setting and planned to include cluster trials. We excluded cross‐over trials. We included studies reported as full‐text articles, those published as abstracts only, and unpublished data. Data collection and analysis At least two review authors screened the search results for eligible studies. We extracted outcome data, assessed risk of bias in duplicate, and resolved discrepancies by involving another review author. We analysed dichotomous data as odds ratios (ORs) or risk differences (RDs), and continuous data as mean differences (MDs), all with a fixed‐effect model. We described skewed data narratively. We graded the results and presented evidence in 'Summary of findings' tables for each comparison. Primary outcomes were intensive care unit/high dependence unit (ICU/HDU) admission, duration of symptoms/exacerbations, and all adverse events. Seconday outcomes were mortality, length of hospital admission, relapse after index presentation, and peak expiratory flow rate (PEFR). Main results Six studies met our inclusion criteria and included a total of 681 adults and children with exacerbations of asthma. Mean age in the three studies in adults ranged from 36.2 to 41.2 years. The three studies in children applied varied inclusion criteria, ranging from one to 18 years of age. Five studies explicitly excluded participants with obvious signs and symptoms of bacterial infection (i.e. those clearly meeting current guidance to receive antibiotics). Four studies investigated macrolide antibiotics, and two studies investigated penicillin (amoxicillin and ampicillin) antibiotics; both studies using penicillin were conducted over 35 years ago. Five studies compared antibiotics versus placebo, and one was open‐label. Study follow‐up ranged from one to twelve weeks. Trials were of varied methodological quality, and we were able to perform only limited meta‐analysis. None of the included trials reported ICU/HDU admission, although one participant in the placebo group of a study including children with status asthmaticus experienced a respiratory arrest and was ventilated. Four studies reported asthma symptoms, but we were able to combine results for only two macrolide studies of 416 participants; the MD in diary card symptom score was ‐0.34 (95% confidence interval (CI) ‐0.60 to ‐0.08), with lower scores (on a 7 point scale) denoting improved symptoms. Two macrolide studies reported symptom‐free days. One study of 255 adults authors reported the percentage of symptom‐free days at 10 days as 16% in the antibiotic group and 8% in the placebo group. In a further study of 40 children study authors reported significantly more symptom‐free days at all time points in the antibiotic group compared with the usual care group. The same study reported the duration in days of the index asthma exacerbation, again favouring the antibiotic group. One study of a penicillin including 69 participants reported asthma symptoms at hospital discharge; the between‐group difference for both studies was reported as non‐significant. We combined data for serious adverse events from three studies involving 502 participants, but events were rare; the three trials reported only 10 events: five in the antibiotic group and five in the placebo group. We combined data for all adverse events (AEs) from three studies, but the effect estimate is imprecise (OR 0.99, 95% CI 0.69 to 1.43). No deaths were reported in any of the included studies. Two studies investigating penicillins reported admission duration; neither study reported a between‐group difference. In one study (263 participants) of macrolides, two participants in each arm were reported as experiencing a relapse, defined as a further exacerbation, by the six‐week time points. We combined PEFR endpoint results at 10 days for two macrolide studies; the result favoured antibiotics over placebo (MD 23.42 L/min, 95% CI 5.23 to 41.60). One study in children reported the maximum peak flow recorded during the follow‐up period, favouring the clarithromycin group, but the confidence interval includes no difference (MD 38.80, 95% CI ‐11.19 to 88.79). Grading of outcomes ranged from moderate to very low quality, with quality of outcomes downgraded for suspicion of publication bias, indirectness, imprecision, and...
- 8 April 2017
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 23, 53-55
Interventions to improve inhaler technique and adherence to inhaled corticosteroids in children with asthma
- 8 April 2017
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 23, 53-55
Interventions to improve inhaler technique and adherence to inhaled corticosteroids in children with asthma